Insilico Medicine, Biopharmaceuticals Strike: AI Drug Deal Heads Toward $2.5B
Insilico Medicine and SK Biopharmaceuticals unveiled a milestone collaboration worth up to $2.5 billion to develop ne...
We examine altcoins with strong funding, evaluating how capital enables development pace, partnerships, and long-term roadmap execution.
17,339 articlesInsilico Medicine and SK Biopharmaceuticals unveiled a milestone collaboration worth up to $2.5 billion to develop ne...
Markets show cautious gains as leaders shift from a tech-first mindset to human-centered growth rooted in local commu...
Investors are pouring capital into a new class of AI startups focused on world models, a movement led by tech founder...
AmeriCraft Homes, backed by veteran developer Art Falcone, launches a Southeast expansion focused on attainable luxur...
Investing in AI requires more than hype. This guide explains how a Nvidia-backed infrastructure stock hand can unlock...
Open Standard's Open USD stablecoin teams with Visa, Stripe, Coinbase and others, promising fee-free minting and reve...
Cramer confronted his past mega-cap bets on Mad Money, pivoting to a bullish view on Corning as supplier demand remai...
UBS researchers say infrastructure stocks have overtaken hyperscalers in AI spending, signaling a shift in AI infrast...
Dram stocks surged on AI-driven demand, yet the rally carries volatility and a stubborn supply gap. This analysis exp...
NuScale Power has sparked excitement around small modular reactors, but does the hype translate into real investing u...
Robinhood launches its on-chain network, sparking a memecoin surge as traders rush into DeFi and tokenized assets. Th...
SK hynix kicked off trading at $170 on the Nasdaq, a 14% jump from the offering price of $149. The $26.5 billion deal...